• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic
Biomed Pharmacother. 2023 Aug 3;165:115254. doi: 10.1016/j.biopha.2023.115254. Online ahead of print.ABSTRACTDespite the development of new biological and synthetic targeted therapies, methotrexate remains one of the most commonly used immunomodulatory drugs in rheumatology. However, its effect on the immunogenicity of vaccines has been studied only to a limited extent until recently, resulting in the lack of clear guidelines on the use of methotrexate during vaccination. Significant progress was made during the COVID-19 pandemic due to the dynamic development of research on vaccines, including patients with autoimmune inf...
Source: Herpes - August 5, 2023 Category: Infectious Diseases Authors: Jakub Wro ński Marzena Ciechomska Ewa Kuca-Warnawin Source Type: research

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial
CONCLUSION: This trial informs safety concerns related to use of live virus vaccines in patients receiving biologics.PRIMARY FUNDING SOURCE: The National Institute of Arthritis and Musculoskeletal and Skin Diseases and the American College of Rheumatology.PMID:34570596 | DOI:10.7326/M20-6928
Source: Annals of Internal Medicine - September 27, 2021 Category: Internal Medicine Authors: Jeffrey R Curtis Stacey S Cofield S Louis Bridges John Bassler Atul Deodhar Theresa L Ford Joseph Huffstutter Allen Jankeel Alan Kivitz Shaila Kamal Stephen Lindsey Ilhem Messaoudi Norma Mendoza Kaleb Michaud Ted R Mikuls David Ridley William Shergy Sarah Source Type: research